

# Jennifer L Caswell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5129876/publications.pdf>

Version: 2024-02-01

26  
papers

1,563  
citations

516710

16  
h-index

610901

24  
g-index

28  
all docs

28  
docs citations

28  
times ranked

4158  
citing authors

#	ARTICLE	IF	CITATIONS
1	8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with <i>MYC</i> . Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9742-9746.	7.1	353
2	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 2019, 567, 399-404.	27.8	239
3	Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectrum, 2018, 2, pky062.	2.9	199
4	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine, 2018, 20, 234-239.	2.4	131
5	Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nature Communications, 2014, 5, 5260.	12.8	123
6	Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative. Journal of the National Cancer Institute, 2019, 111, 95-98.	6.3	81
7	Analysis of Chimpanzee History Based on Genome Sequence Alignments. PLoS Genetics, 2008, 4, e1000057.	3.5	73
8	Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nature Communications, 2019, 10, 657.	12.8	43
9	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 2020, 11, 5824.	12.8	42
10	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nature Cancer, 2021, 2, 400-413.	13.2	41
11	Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data. JAMIA Open, 2019, 2, 528-537.	2.0	40
12	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications, 2015, 6, 7539.	12.8	38
13	Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nature Medicine, 2019, 25, 1721-1727.	30.7	27
14	Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 995.	7.4	26
15	Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors. Human Molecular Genetics, 2015, 24, 7421-7431.	2.9	24
16	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. Cancer, 2021, 127, 3742-3750.	4.1	21
17	Molecular Heterogeneity and Evolution in Breast Cancer. Annual Review of Cancer Biology, 2021, 5, 79-94.	4.5	14
18	Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population. Breast Cancer Research and Treatment, 2022, 194, 475-482.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. JCO Precision Oncology, 2018, 2, 1-10.	3.0	7
20	Androgen receptor agonists as breast cancer therapeutics. Nature Medicine, 2021, 27, 198-199.	30.7	7
21	Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics, 2021, 5, 600-614.	2.1	5
22	Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Modern Pathology, 2022, 35, 1349-1361.	5.5	5
23	High mammographic density in women of Ashkenazi Jewish descent. Breast Cancer Research, 2013, 15, R40.	5.0	4
24	Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice, 2016, 12, 763-764.	2.5	1
25	Response to Peshkin, Isaacs, and Schwartz. Journal of the National Cancer Institute, 2019, 111, 874-874.	6.3	0
26	Patient perspectives on window of opportunity clinical trials in early-stage breast cancer. Breast Cancer Research and Treatment, 2022, , 1.	2.5	0